Research programme: Alzheimer's disease therapeutics - Amgen

Drug Profile

Research programme: Alzheimer's disease therapeutics - Amgen

Alternative Names: AMG-0683; CMP 015

Latest Information Update: 02 Sep 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Class Amides; Aminoquinolines
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 26 Aug 2010 Preclinical pharmacodynamics data in Alzheimer's disease presented at the 240th American Chemical Society National Meeting (240th-ACS-2010)
  • 21 Oct 2009 Preclinical pharmacodynamics data in Alzheimer's disease presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 20 Aug 2009 Preclinical trials in Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top